Leadership Overview
Cohance Lifesciences has 4 executives leading key functions including corporate strategy, API and formulation development, platform operations, and technology manufacturing.
Focused on accelerating pharmaceutical innovation through advanced CDMO services, Cohance Lifesciences delivers integrated solutions for complex molecule development while maintaining a steadfast commitment to global sustainability and quality standards.
Focused on accelerating pharmaceutical innovation through advanced CDMO services, Cohance Lifesciences delivers integrated solutions for complex molecule development while maintaining a steadfast commitment to global sustainability and quality standards.
Leadership Roles at Cohance Lifesciences
Umang Vohra - Executive Chairman & Global Chief Executive Officer
Umang Vohra, the Executive Chairman & Global Chief Executive Officer at Cohance Lifesciences, directs the overarching corporate strategy and long-term vision for the organization. Overseeing global market expansion, the Executive Chairman & Global Chief Executive Officer ensures alignment between internal development capabilities and the evolving needs of pharmaceutical innovators. This leadership role involves managing high-level partnerships and driving the company toward commercial scale in the competitive CDMO landscape. By prioritizing sustainable growth and operational excellence, Umang Vohra directly impacts the trajectory of the business. Through rigorous oversight of international operations, the Executive Chairman & Global Chief Executive Officer secures the firm's position as a leader in Antibody Drug Conjugates and Small Molecules. Ultimately, Vohra maintains the integrity of the global pipeline while fostering innovation across all clinical analytical service divisions.

Gunjan Singh - Chief Executive Officer, Api Plus (Api & Formulations)
Gunjan Singh, the Chief Executive Officer, Api Plus (Api & Formulations) at Cohance Lifesciences, manages the end-to-end development and manufacturing of active pharmaceutical ingredients and complex formulations. Overseeing the API division, the Chief Executive Officer, Api Plus (Api & Formulations) ensures that all production processes meet stringent quality benchmarks for global clients. This leadership role involves scaling manufacturing capacity to support pharmaceutical innovators from discovery through commercialization. By optimizing chemical synthesis workflows, Gunjan Singh directly influences the efficiency of the drug development pipeline. Through strategic coordination with internal research teams, the Chief Executive Officer, Api Plus (Api & Formulations) drives the adoption of advanced manufacturing techniques. Ultimately, Singh secures the company's reputation for excellence in small molecule production and formulation services across diverse international markets.
Ravinath Shetty - Chief Operating Officer, Platform
Ravinath Shetty, the Chief Operating Officer, Platform at Cohance Lifesciences, architects the operational framework supporting the company's specialized CDMO service offerings. Overseeing the integration of Nucleic Acid Chemistry and ADC platforms, the Chief Operating Officer, Platform ensures seamless execution of complex development projects. This leadership role involves streamlining cross-functional workflows to enhance service delivery speed for pharmaceutical partners. By refining the operational infrastructure, Ravinath Shetty directly impacts the scalability of the firm's technical capabilities. Through constant monitoring of platform performance, the Chief Operating Officer, Platform maintains high standards of precision in clinical analytical services. Ultimately, Shetty drives the operational efficiency required to support the company's mission of accelerating the pipeline for innovators, ensuring that all platform-based initiatives align with broader corporate objectives and market demands.
Sunil Uttarwar - Chief Operating Officer, Technology Operations
Sunil Uttarwar, the Chief Operating Officer, Technology Operations at Cohance Lifesciences, directs the technical manufacturing infrastructure and facility management across the organization. Overseeing the implementation of advanced manufacturing technologies, the Chief Operating Officer, Technology Operations ensures that all production sites maintain peak operational readiness and compliance. This leadership role involves managing the transition of complex molecules from laboratory settings to large-scale commercial manufacturing. By optimizing facility throughput and resource allocation, Sunil Uttarwar directly supports the company's commitment to quality and sustainability. Through the modernization of technical systems, the Chief Operating Officer, Technology Operations enhances the firm's ability to handle intricate chemical processes. Ultimately, Uttarwar secures the reliability of the supply chain, ensuring that all technology-driven operations meet the rigorous requirements of global pharmaceutical clients.

Explore Leadership Teams in Manufacturing
Boehringer Ingelheim is a privately held, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, founded in 1885. The company researches, develops, and manufactures prescription medicines and healthcare products across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Its primary therapeutic focus areas include respiratory diseases, oncology, immunology, cardiometabolic conditions, and central nervous system disorders. Boehringer Ingelheim also develops and manufactures veterinary products for companion animals, livestock, and poultry. Operating in over 100 countries with more than 53,000 employees globally, the company maintains a broad network of research, manufacturing, and commercial sites across Europe, North America, and Asia. It is one of the largest privately owned pharmaceutical companies in the world.
Company Leadership KE
KY
DP
PL
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Company Leadership
AD
RS
KH
Founded in 1967, Douglas Pharmaceuticals is a manufacturer of pharmaceutical products. The company started out distributing prescription medicines, before manufacturing and later successfully researching and developing its products for export. The company is headquartered in Auckland, New Zealand.
Company Leadership AC

KF
CR
Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery.
Company Leadership DS

BS